15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
Incyte Corp (INCY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 30,739,466 | $2,123,174,917 | +1% | 22.67% |
| 2. | Renaissance Technologies Jim Simons | 4,085,932 | $282,215,323 | -10% | 0.41% |
| 3. | AQR Capital Management Cliff Asness | 3,502,813 | $241,518,963 | +30% | 0.31% |
| 4. | Armistice Capital Steven Boyd | 1,767,830 | $122,104,018 | -20% | 1.66% |
| 5. | Point72 Asset Management Steve Cohen | 1,278,369 | $88,296,965 | -47% | 0.19% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $73.31 | 175,795 | Large Shareholder, Director | 33,419,055 | 2022-03-10 | Filing | |
| $73.31 | 14,490 | Large Shareholder, Director | 2,941,147 | 2022-03-10 | Filing | |
| $71.95 | 1,017 | Large Shareholder, Director | 33,243,260 | 2022-03-10 | Filing | |
| $71.95 | 84 | Large Shareholder, Director | 2,926,657 | 2022-03-10 | Filing | |
| $71.90 | 25,107 | Large Shareholder, Director | 33,242,243 | 2022-03-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $67.68 | 19,147 | Officer | 33,567 | 2025-03-14 | Filing | |
| $67.88 | 199 | Officer | 52,714 | 2025-03-14 | Filing | |
| $67.85 | 461 | Officer | 52,913 | 2025-03-14 | Filing | |
| $69.99 | 599 | Officer | 25,848 | 2025-03-04 | Filing | |
| $74.08 | 4,495 | Officer | 25,848 | 2025-02-26 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 19,580,477 | $1,352,423,546 | 0.02% | |
| 2. | 16,510,467 | $1,140,377,896 | 0.02% | |
| 3. | 14,919,633 | $1,030,499,051 | 0.59% | |
| 4. | 10,031,136 | $692,821,155 | 0.02% | |
| 5. | 4,040,086 | $278,345,675 | 0.02% |
News See All
10 Best Immunology Stocks To Buy Now
Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.
12 AI Updates Worth Taking a Look At
In a Bloomberg interview, SandboxAQ CEO Jack Hidary started discussing the company's partnership with Saudi Aramco, which focuses on using AI to convert carbon emissions into valuable products.
Incyte Corporation (NASDAQ:INCY) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Incyte Fourth Quarter 2024 and Full Year Financial and Corporate Update Conference Call and Webcast. At this time all participants are in listen-only mode.
Goldman Sachs' Top Growth Investors: 34 Stocks With The Highest Investment For Growth
With the 2024 US Presidential Election having come to a close, Wall Street can now focus on the future of artificial intelligence, the Federal Reserve's interest rate cut cycle, and an economy with lower...
10 Best Immunotherapy Stocks to Buy Now
The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by 2033.
Here’s How Jakafi’s Patent Expiry Impacts Incyte Corporation’s (INCY) Growth Prospects
Many investors continue to be worried about Incyte’s financial prospects when the patent for the company’s blood cancer medication, Jakafi, expires in 2028.
Incyte Corporation (NASDAQ:INCY) Q3 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the Incyte Third Quarter Financial Results Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded.
Incyte Corporation (NASDAQ:INCY) Q2 2024 Earnings Call Transcript
Operator: Hello, and welcome to the Incyte Second Quarter 2024 Earnings Conference Call. [Operator Instructions] A question-and-answer session will follow the formal presentation.
Incyte Corporation (NASDAQ:INCY) Q1 2024 Earnings Call Transcript
Incyte Corporation misses on earnings expectations. Reported EPS is $0.746 EPS, expectations were $0.88.
Billionaire Hedge Funds
